Aleix Prat: HER2DX is Now Available in Argentina Through Omics Argentina
Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinic Hospital, shared a post on LinkedIn by Omics Argentina, adding:
“Very happy that HER2DX is now available in Argentina through Omics Argentina.
It is exciting to see how the innovation we develop from the laboratory reaches more and more patients and doctors in the world.
Next week I will be in Buenos Aires at the 2025 AAOC Congress, and we will have time to talk about the test.”
Quoting Omics Argentina’s post below:
“HER2DX is now available in Argentina
It is the first genomic test designed for patients with early-stage HER2+ breast cancer, providing clinicians with key information to guide treatment decisions. HER2DX combines immune and tumor biology with clinical data to:
– Optimize the choice of treatment, avoiding over- and under-treatment.
– Provide clear and easy-to-interpret results.
– Validated in more than 2,000 patients, HER2DX offers three high-value clinical scores:
Risk Score to Long-term risk of relapse. pCR Likelihood Score to Probability of response to neoadjuvant anti-HER2 therapy.
ERBB2 Score to Expression level of the ERBB2 gene.
With solid scientific evidence and an easy-to-interpret report, HER2DX® arrives to redefine precision oncology in the treatment of HER2+ breast cancer in Argentina.”
More Posts Featuring Aleix Prat.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023